{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:35:21Z","timestamp":1793212521224,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.09.035","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:25:14Z","timestamp":1790576714000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Planning advanced therapy trials for Huntington\u2019s disease: Ethical considerations"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2785-4623","authenticated-orcid":false,"given":"Cindy","family":"Towns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4397-6252","authenticated-orcid":false,"given":"Cheney","family":"Drew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.09.035_bib1","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1007\/s00415-022-11085-z","article-title":"Risk of mortality from suicide in patients with Huntington\u2019s disease is increased compared to the general population in England","volume":"269","author":"Alothman","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib2","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/hmg\/ddaa139","article-title":"Patterns of CAG repeat instability in the central nervous system and periphery in Huntington\u2019s disease and in spinocerebellar ataxia type 1","volume":"29","author":"Mouro Pinto","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib4","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/mds.70361","article-title":"Systematic Review of the Huntington\u2019s Disease Drug Development Pipeline, 2014 to 2025","volume":"41","author":"Konstantinova","year":"2026","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2026.09.035_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/d41586-025-03139-9","article-title":"Huntington\u2019s disease treated for first time using gene therapy","volume":"646","author":"Dolgin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.035_bib7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/brain\/awac086","article-title":"Translating cell therapies for neurodegenerative diseases: Huntington\u2019s disease as a model disorder","volume":"145","author":"Rosser","year":"2022","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.09.035_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1467-8519.1991.tb00142.x","article-title":"Fetal neural transplantation: placing the ethical debate within the context of society\u2019s use of human material","volume":"5","author":"JONES","year":"1991","journal-title":"Bioethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2016.10.012","article-title":"The science and ethics of cell-based therapies for Parkinson\u2019s disease","volume":"34","author":"Towns","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ymthe.2026.09.035_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/stem.3300","article-title":"Cell therapy in Huntington\u2019s disease: Taking stock of past studies to move the field forward","volume":"39","author":"Bachoud-L\u00e9vi","year":"2021","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2026.09.035_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/jme.2003.002386","article-title":"Stem cells, embryos, and the environment: A context for both science and ethics","volume":"30","author":"Towns","year":"2004","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib13","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1093\/hmg\/ddn074","article-title":"The road to pluripotence: the research response to the embryonic stem cell debate","volume":"17","author":"Scott","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib14","first-page":"8716","article-title":"THE NEW ZEALAND MEDICAL JOURNAL Where does New Zealand stand on permitting research on human embryos?","volume":"127","author":"Jones","year":"2014","journal-title":"J. New Zealand Med. Assoc. NZMJ"},{"key":"10.1016\/j.ymthe.2026.09.035_bib15","first-page":"1009","article-title":"NIH report on human embryo research","volume":"344","author":"Rowe","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.035_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/j.1552-146X.1999.tb00050.x","article-title":"Research with Human Embryonic Stem Cells: Ethical Considerations","volume":"29","author":"Lebacqz","year":"1999","journal-title":"Hastings Cent. Rep."},{"key":"10.1016\/j.ymthe.2026.09.035_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1353\/ken.1999.0011","article-title":"The ethics of funding embryonic stem cell research: a Catholic viewpoint","volume":"9","author":"Doerflinger","year":"1999","journal-title":"Kennedy Inst. Ethics J."},{"key":"10.1016\/j.ymthe.2026.09.035_bib18","first-page":"204","article-title":"Ethical issues in human stem cell research executive summary","volume":"30","author":"Rockville","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ymthe.2026.09.035_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1017\/S0730938400006614","article-title":"Embryo disposal practices in IVF clinics in the United States","volume":"22","author":"Gurmankin","year":"2003","journal-title":"Polit. Life Sci."},{"key":"10.1016\/j.ymthe.2026.09.035_bib20","first-page":"22","article-title":"Stem cells: public policy and ethics","volume":"5","author":"Towns","year":"2004","journal-title":"N. Z. Bioeth. J."},{"key":"10.1016\/j.ymthe.2026.09.035_bib21","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/humrep\/dei461","article-title":"Navigating the quagmire: the regulation of human embryonic stem cell research","volume":"21","author":"Jones","year":"2006","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ymthe.2026.09.035_bib24","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.stem.2021.10.008","article-title":"The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions","volume":"28","author":"Turner","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.09.035_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00435","article-title":"Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?","volume":"21","author":"Harkins","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102532","article-title":"Engineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system","volume":"83","author":"Carneiro","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib31","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","article-title":"Advances in AAV capsid engineering: Integrating rational design, directed evolution and machine learning","volume":"33","author":"Nisanov","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biotechadv.2016.12.003","article-title":"Detection of on-target and off-target mutations generated by CRISPR\/Cas9 and other sequence-specific nucleases","volume":"35","author":"Zischewski","year":"2017","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ymthe.2026.09.035_bib34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/encyclopedia3040096","article-title":"Gene Editing: The Regulatory Perspective","volume":"3","author":"Prisco","year":"2023","journal-title":"Encyclopedia"},{"key":"10.1016\/j.ymthe.2026.09.035_bib35","series-title":"Guidance for Industry","article-title":"Long Term Follow-Up After Administration of Human Gene Therapy Products","year":"2020"},{"key":"10.1016\/j.ymthe.2026.09.035_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-022-01574-0","article-title":"Inadequate reporting quality of registered genome editing trials: an observational study","volume":"22","author":"Juri\u0107","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/hum.2016.172","article-title":"Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy","volume":"28","author":"Ertl","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib39","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0140-6736(19)33137-X","article-title":"Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines)","volume":"395","author":"Beard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.09.035_bib40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jama.1961.63040260007008","article-title":"Surgery as placebo. A quantitative study of bias","volume":"176","author":"Beecher","year":"1961","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2026.09.035_bib41","first-page":"21","article-title":"Gene Therapy for Huntington\u2019s Disease Faces New Regulatory Hurdle","volume":"26","author":"Shaw","year":"2026","journal-title":"Neurol. Today"},{"key":"10.1016\/j.ymthe.2026.09.035_bib42","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJM199909233411312","article-title":"The Ethical Problems with Sham Surgery in Clinical Research","volume":"341","author":"Macklin","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6939-15-78","article-title":"Strengthening the ethical assessment of placebo-controlled surgical trials: three proposals","volume":"15","author":"Rogers","year":"2014","journal-title":"BMC Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/medethics-2015-103333","article-title":"Randomised placebo-controlled trials of surgery: ethical analysis and guidelines","volume":"42","author":"Savulescu","year":"2016","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3233\/JPD-191577","article-title":"Evidence-Based Evaluation of the Ethics of Sham Surgery for Parkinson\u2019s Disease","volume":"9","author":"Polgar","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2026.09.035_bib46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.stem.2023.12.004","article-title":"Sham surgery for the trialing of cell-based therapies to the CNS may not be necessary","volume":"31","author":"Tabar","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.09.035_bib47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/eahr.500007","article-title":"A Framework for Assessing Scientific Merit in Ethical Review of Clinical Research","volume":"41","author":"Binik","year":"2019","journal-title":"Ethics Hum. Res."},{"key":"10.1016\/j.ymthe.2026.09.035_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040324","article-title":"Clinical Trials and Medical Care: Defining the Therapeutic Misconception","volume":"4","author":"Henderson","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/bs.irn.2022.09.006","article-title":"Considerations for clinical trial design and conduct in the evaluation of novel advanced therapeutics in neurodegenerative disease","volume":"166","author":"Drew","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib51","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.pain.2014.09.029","article-title":"Placebo use in pain management: The role of medical context, treatment efficacy, and deception in determining placebo acceptability","volume":"155","author":"Kisaalita","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2026.09.035_bib52","series-title":"Principles of Biomedical Ethics - Paperback","first-page":"453","author":"Childress","year":"2001"},{"key":"10.1016\/j.ymthe.2026.09.035_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000509119","article-title":"Principles of Clinical Ethics and Their Application to Practice","volume":"30","author":"Varkey","year":"2021","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.ymthe.2026.09.035_bib54","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/gim.2013.148","article-title":"\u201cIs a cure in my sight?\u201d Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials","volume":"16","author":"Benjaminy","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1472-6939-15-58","article-title":"Ocular gene transfer in the spotlight: implications of newspaper content for clinical communications","volume":"15","author":"Benjaminy","year":"2014","journal-title":"BMC Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.socscimed.2005.05.022","article-title":"Therapeutic misconception in early phase gene transfer trials","volume":"62","author":"Henderson","year":"2006","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/B978-0-12-398523-1.00071-9","article-title":"Ethics in Regenerative Medicine and Transplantation","author":"King","year":"2014","journal-title":"Regenerative Med. Appl. Organ. Transplant."},{"key":"10.1016\/j.ymthe.2026.09.035_bib58","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jbusres.2022.02.026","article-title":"Innovation and misconduct in the pharmaceutical industry","volume":"144","author":"Arnold","year":"2022","journal-title":"J. Bus. Res."},{"key":"10.1016\/j.ymthe.2026.09.035_bib59","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1038\/s41467-020-20096-1","article-title":"Patient and public perspectives on cell and gene therapies: a systematic review","volume":"11","author":"Aiyegbusi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.09.035_bib60","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/jme.2007.021857","article-title":"Payment for research participation: a coercive offer?","volume":"34","author":"Wertheimer","year":"2008","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/15265161.2019.1630497","article-title":"How Payment for Research Participation Can Be Coercive","volume":"19","author":"Millum","year":"2019","journal-title":"Am. J. Bioeth."},{"key":"10.1016\/j.ymthe.2026.09.035_bib62","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/bmj.p686","article-title":"When science goes wrong\u2014misrepresentation, coercion, and undue influence when paying research participants","volume":"380","author":"Nordling","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.09.035_bib63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11019-022-10092-1","article-title":"The ethical anatomy of payment for research participants","author":"R\u00f3\u017cy\u0144ska","year":"2022","journal-title":"Med. Health Care Philos."},{"key":"10.1016\/j.ymthe.2026.09.035_bib64","first-page":"61","article-title":"Paying Research Participants: Regulatory Uncertainty, Conceptual Confusion, and a Path Forward","volume":"17","author":"Largent","year":"2017","journal-title":"Yale J. Health Policy L. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/medethics-2020-107060","article-title":"Fair go: pay research participants properly or not at all","volume":"46","author":"Grimwade","year":"2020","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib66","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/medethics-2020-106438","article-title":"Payment in challenge studies: ethics, attitudes and a new payment for risk model","volume":"46","author":"Grimwade","year":"2020","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.29443","article-title":"Assessing Psychosocial Risk and Resilience to Support Readiness for Gene Therapy in Sickle Cell Disease: A Consensus Statement","volume":"7","author":"Hardy","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ymthe.2026.09.035_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/hae.70165","article-title":"A Comprehensive Approach: Addressing Psychological Needs in Gene Therapy for Haemophilia","volume":"32","author":"Peyvandi","year":"2026","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2026.09.035_bib69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13023-023-02680-y","article-title":"\u201cI just wanted to speak to someone- and there was no one\u2026\u201d: using Burden of Treatment Theory to understand the impact of a novel ATMP on early recipients","volume":"18","author":"Litchfield","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2026.09.035_bib71","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/jme-2023-109719","article-title":"Need for greater post-trial support for clinical trial participants assessing high-risk, irreversible treatments","volume":"51","author":"Harris","year":"2025","journal-title":"J. Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/bs.irn.2022.09.007","article-title":"More than a participant in trials of cell and gene therapy: Hearing the voices of people living with neurodegenerative diseases","volume":"166","author":"Lane","year":"2022","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib73","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in Adults with Manifest Huntington\u2019s Disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib74","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1001\/jamaneurol.2019.4974","article-title":"Rescuing Research Participants After Alzheimer Trials Stop Early: Sending Out an SOS","volume":"77","author":"Largent","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib75","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/brain\/awz023","article-title":"Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson\u2019s disease","volume":"142","author":"Whone","year":"2019","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2026.09.035_bib76","series-title":"Patient-Focused Drug Development: Collecting Comprehensive and Representative Input","year":"2018"},{"key":"10.1016\/j.ymthe.2026.09.035_bib77","article-title":"Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU","volume":"11","author":"Almeida","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.ymthe.2026.09.035_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111617","article-title":"Patient-reported outcomes and measures are under-utilised in advanced therapy medicinal products trials for orphan conditions","volume":"178","author":"Ciuca","year":"2025","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib80","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: the Integrated Staging System","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib81","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/laws7020017","article-title":"Concerns about Genetic Discrimination after Regulation: A Qualitative Study of the Situation Regarding BRCA and Huntington\u2019s Disease in Belgium","volume":"7","author":"Wauters","year":"2018","journal-title":"Laws"},{"key":"10.1016\/j.ymthe.2026.09.035_bib82","first-page":"15","article-title":"ETHICAL AND GENETIC ASPECTS REGARDING PRESYMPTOMATIC TESTING FOR NEURODEGENERATIVE DISEASES - PubMed","volume":"120","author":"Cozaru","year":"2016","journal-title":"Rev. Med. Chir. Soc. Med. Nat. Iasi"},{"key":"10.1016\/j.ymthe.2026.09.035_bib83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-444-63233-3.00003-8","article-title":"Ethical issues in neurogenetics","volume":"147","author":"Uhlmann","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ymthe.2026.09.035_bib84","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/mds.29963","article-title":"Time to Functional Loss as an Endpoint in Huntington\u2019s Disease Trials: Enrichment and Sample Size","volume":"39","author":"Mills","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymthe.2026.09.035_bib86","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1010517","article-title":"Genomics, Health Care, and Society","volume":"365","author":"Hudson","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib90","series-title":"Charter of Fundamental Rights of the European Union","year":"2012"},{"key":"10.1016\/j.ymthe.2026.09.035_bib91","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajmg.1320540304","article-title":"Psychological costs and benefits of predictive testing for Huntington\u2019s disease","volume":"54","author":"Codori","year":"1994","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2018.00624","article-title":"A Systematic Review of the Psychological Implications of Genetic Testing: A Comparative Analysis Among Cardiovascular, Neurodegenerative and Cancer Diseases","volume":"9","author":"Oliveri","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib93","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1399-0004.2012.01900.x","article-title":"Recommendations for the predictive genetic test in Huntington\u2019s disease","volume":"83","author":"Macleod","year":"2013","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib94","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/ejhg.2017.139","article-title":"22 Years of predictive testing for Huntington\u2019s disease: the experience of the UK Huntington\u2019s Prediction Consortium","volume":"25","author":"SS","year":"2017","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib95","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ajmg.b.32582","article-title":"Predictive testing of minors for Huntington\u2019s disease: The UK and Netherlands experiences","volume":"177","author":"Quarrell","year":"2018","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41431-018-0255-7","article-title":"Reverse pre-symptomatic testing for Huntington disease: double disclosure when 25% at-risk children reveal the genetic status to their parent","volume":"27","author":"Bonnard","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib99","first-page":"365","article-title":"The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies","volume":"37","author":"Sabatini","year":"2023","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib100","first-page":"674","article-title":"Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies","volume":"27","author":"Garrison","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.ymthe.2026.09.035_bib101","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41434-023-00419-9","article-title":"The estimated annual financial impact of gene therapy in the United States","volume":"30","author":"Wong","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib102","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41434-023-00419-9","article-title":"The estimated annual financial impact of gene therapy in the United States","volume":"30","author":"Wong","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib103","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ajmg.c.32037","article-title":"A review of economic issues for gene-targeted therapies: Value, affordability, and access","volume":"193","author":"Garrison","year":"2023","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"10.1016\/j.ymthe.2026.09.035_bib104","first-page":"265","article-title":"Pricing and Market Access Challenges in the Era of One-Time Administration Cell and Gene Therapies","volume":"36","author":"Sabatini","year":"2022","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s41649-019-00100-7","article-title":"Big Data and Public-Private Partnerships in Healthcare and Research: The Application of an Ethics Framework for Big Data in Health and Research","volume":"11","author":"Ballantyne","year":"2019","journal-title":"Asian Bioeth. Rev."},{"key":"10.1016\/j.ymthe.2026.09.035_bib106","author":"Sherkow"},{"key":"10.1016\/j.ymthe.2026.09.035_bib107","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nm0313-261","article-title":"Bioethical accreditation or rating needed to restore trust in pharma","volume":"19","author":"Miller","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/20539517221108988","article-title":"Sharing precision medicine data with private industry: Outcomes of a citizens\u2019 jury in Singapore","volume":"9","author":"Ballantyne","year":"2022","journal-title":"Big Data Soc."},{"key":"10.1016\/j.ymthe.2026.09.035_bib109","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1472-6939-14-36","article-title":"Benefit sharing: an exploration on the contextual discourse of a changing concept","volume":"14","author":"Dauda","year":"2013","journal-title":"BMC Med. Ethics"},{"key":"10.1016\/j.ymthe.2026.09.035_bib110","series-title":"Health Technology for All: An Equity-Based Paradigm Shift Opportunity","author":"MacDonald","year":"2022"},{"key":"10.1016\/j.ymthe.2026.09.035_bib111","first-page":"1111","article-title":"Drug companies are ignoring health crisis in poor countries, Oxfam says","volume":"335","author":"O\u2019Dowd","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.09.035_bib112","article-title":"Advancing the inclusion of underrepresented women in clinical research","volume":"3","author":"Bierer","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib113","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1370\/afm.2901","article-title":"Recruiting Indigenous Patients Into Clinical Trials: A Circle of Trust","volume":"21","author":"Mainous","year":"2023","journal-title":"Ann. Fam. Med."},{"key":"10.1016\/j.ymthe.2026.09.035_bib114","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.ymthe.2018.11.002","article-title":"Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy","volume":"26","author":"Cornetta","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib115","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.09.035_bib116","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10728-007-0045-9","article-title":"Embryonic stem cell patents and human dignity","volume":"15","author":"Resnik","year":"2007","journal-title":"Health Care Anal."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:58:53Z","timestamp":1793210333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626008026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":102,"alternative-id":["S1525001626008026"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.035","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Planning advanced therapy trials for Huntington\u2019s disease: Ethical considerations","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}